Communiqués Clene Inc.

Actions

CLNN

US1856341029

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
0,3562 ^USD	-3,47 %		-10,12 %	+20,09 %

21/06	Clene annonce que son principal candidat-médicament présente un potentiel pour le traitement du syndrome de Rett	MT
21/06	Clene Inc. et Clene Nanomedicine Inc. présentent des données préliminaires sur le CNM-Au8 en tant que traitement potentiel du syndrome de Rett	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference	24/06	AQ
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome	21/06	AQ
Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting	18/06	AQ
Clene to Present at the Emerging Growth Conference	05/06	AQ
Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)	28/05	AQ
Clene to Present at Upcoming May Conferences	14/05	AQ
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights	08/05	AQ
IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington	01/05	AQ
Clene : 2023 Annual Report to Stockholders	17/04	PU
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting	16/04	AQ
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington	19/03	AQ
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®	15/03	AQ
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights	13/03	AQ
Clene to Present at the 36th Annual ROTH Conference	07/03	AQ
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024	29/02	AQ
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs	22/02	AQ
Clene Inc. announces positive results from CNM-Au8 results from MS trial	05/02	AQ
Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension	08/01	AQ
Clene Provides Update on ALS Clinical Development Meeting With FDA	21/12	AQ
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension	21/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Clene Inc.

Actions

CLNN

US1856341029

Communiqués

Filtres